Literature DB >> 2173281

Prevalence of anti-HCV antibody in blood donors in the Tokyo area.

J Watanabe1, K Minegishi, T Mitsumori, M Ishifuji, T Oguchi, M Ueda, E Tokunaga, E Tanaka, K Kiyosawa, S Furuta.   

Abstract

Prospective studies of posttransfusion hepatitis carried out in the past decade showed that 18.1% of the blood transfusions resulted in non-A non-B hepatitis in Japan. As an approach to the prevention of posttransfusion non-A non-B hepatitis (PTNANB), anti-hepatitis C virus (HCV) positivity was measured in 2,970 blood donations in the Tokyo area, and in 200 children aged between 6 and 15 years. Thirty-four cases were anti-HCV-positive, showing an overall positivity of 1.14%. None of the 200 children younger than 15 years old were positive. Correlation of anti-HCV positivity with the serum ALT levels was observed, but by reducing the accepted ALT levels from 35 Karmen Units (KU) down to 25 KU, it is estimated that 62.5% of the observed PTNANB would still have occurred, and 5.1% of the donated blood could not be used for transfusion. On the other hand, it is estimated that the majority of PTNANB could be prevented, with the loss of 1.14% of donated blood units, using the anti-HCV screening test.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173281     DOI: 10.1111/j.1423-0410.1990.tb05015.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  19 in total

Review 1.  Clinical aspects and epidemiology of hepatitis B and C viruses in hepatocellular carcinoma in Japan.

Authors:  K Kiyosawa; S Furuta
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

3.  Prevalence of antibodies to recombinant hepatitis C virus protein C100-3 and of elevated transaminase levels in blood donors from Northern Germany.

Authors:  G Caspari; J Beyer; K Richter; W H Gerlich; H Schmitt
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

4.  Occurrence of hepatocellular carcinoma in chronic viral hepatitis.

Authors:  M Omata; S Takano
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Intrafamilial transmission of hepatitis C virus in Japan.

Authors:  K Michitaka; M Onji; N Horiike; K Kajino; I Saito; T Miyamura; Y Ohta
Journal:  Gastroenterol Jpn       Date:  1991-10

Review 6.  Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Authors:  H B Slade
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

7.  Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases.

Authors:  S Takano; M Omata; M Ohto; Y Satomura
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

8.  Rationale for preoperative screening of anti-HCV antibody.

Authors:  Y Sakaguchi; S Inaba; J Yoshitake
Journal:  J Anesth       Date:  1993-01       Impact factor: 2.078

9.  Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan.

Authors:  H Tanaka; T Hiyama; H Tsukuma; Y Okubo; H Yamano; A Kitada; I Fujimoto
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

10.  Clinical and epidemiologic characteristics of hepatitis C in a gastroenterology/hepatology practice in Ottawa.

Authors:  L J Scully; S Mitchell; P Gill
Journal:  CMAJ       Date:  1993-04-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.